ABOUT CORIOLIS PHARMA
Coriolis Pharma is a globally operating, science-driven Contract Research and Development Organization (CRDO). We provide integrated services in drug product development, analytical testing, and manufacturing support for liquid, frozen-liquid, and lyophilized drug products across all stages—from early development through commercialization and lifecycle management.
Our core expertise includes formulation development and analytical services delivered under both R&D and GMP conditions. Industry-experienced scientists design and execute platform and custom services for a broad range of biopharmaceutical modalities, including biologics, cell and gene therapies, and vaccines. We operate state-of-the-art laboratories in Martinsried, Germany and Durham, NC, USA and maintain a presence across Europe and the United States. Our services cover drug product development, analytical testing, and manufacturing support, with dedicated local project management enabling close collaboration and efficient communication throughout the project lifecycle.
FEATURED WEBINARS
-
![Formulating The Future: A Practical Guide To Nucleic Acid Therapeutics]( "Formulating The Future: A Practical Guide To Nucleic Acid Therapeutics")
Formulating The Future: A Practical Guide To Nucleic Acid TherapeuticsAn expert-led webinar exploring nucleic acid therapeutic modalities, delivery systems, formulation challenges, and real-world case studies shaping drug product development.
-
![The Road To Success]( "Drug Product Development: Preclinical To Commercial")
Drug Product Development: Preclinical To CommercialWatch a unified roadmap for drug product development, outlining phase‑appropriate studies, QTTP importance, and key requirements from preclinical stages through commercialization.
-
![Shedding Light On Surfactants Used As Excipient For Biologics]( "Understanding Surfactant Excipients In Biologic Formulations")
Understanding Surfactant Excipients In Biologic FormulationsUncover surfactant characterization, polysorbate degradation, and advanced analytics, such as multidimensional LC, to strengthen stability assessment and formulation for biologics and advanced therapies.
-
![Subvisible Particle Analysis]( "Subvisible Particle Analysis For End‑To‑End Quality")
Subvisible Particle Analysis For End‑To‑End QualitySee strategies for precise subvisible particle analysis, covering regulatory expectations, method validation, and controlling variability when transitioning workflows from R&D to GMP environments.
-
![Paving The Way To A Successful AAV Product]( "Building A Path To A Successful AAV Product")
Building A Path To A Successful AAV ProductSee state‑of‑the‑art analytical methods for AAV characterization, key quality attributes to monitor, and approaches for measuring infectivity and full‑to‑empty capsid ratios.
FEATURED ARTICLES
-
![clinical-drug-development-GettyImages-1354172647]( "Advancing Formulation Strategies for Complex Drug Products")
Advancing Formulation Strategies for Complex Drug ProductsAn event-focused overview examining how formulation development and stability strategies support robust, scalable drug products discussed at the DDF Summit Berlin.
-
![pharma-development-GettyImages-2166352610]( "Strengthening Drug Product CMC through Drug Product Science | AAPS")
Strengthening Drug Product CMC through Drug Product Science | AAPSAt AAPS, drug product experts discuss how formulation, stability, and analytical services enable robust CMC strategies, reduce development risk, and support confident regulatory decision‑making.
-
![GettyImages-2180925562-syringe-needle-peptide-glp-1]( "Managing CMC Risk For Complex Peptide And Nucleic Acid Therapeutics")
Managing CMC Risk For Complex Peptide And Nucleic Acid TherapeuticsAt TIDES USA 2026, experts discuss how formulation science, stability strategies, and advanced analytics help reduce CMC risk and enable confident development of peptide and nucleic acid therapeutics.
-
![investors-biotech-GettyImages-1498705688]( "Derisking And Accelerating Drug Development With Expertise")
Derisking And Accelerating Drug Development With ExpertiseScientific expertise and tailored development approaches reduce risk, boost stability and manufacturability, and accelerate drug programs toward commercialization.
-
![GettyImages-1087219526-scientist-computer-screen-compliance-sterilization]( "Developability And Pre‑Formulation For A Faster Path To Approval")
Developability And Pre‑Formulation For A Faster Path To ApprovalDevelopability and pre‑formulation screening uncover risks, inform molecule selection, and shorten development to reduce failures and accelerate approval.
CONTACT INFORMATION
Coriolis Pharma
Fraunhoferstraße 18b
Martinsried/Munich, 82152
GERMANY
Contact: https://www.coriolis-pharma.com/contact/
U.S. FACILITIES
BROCHURES
-
![GettyImages-2213157127-drug-formulation-discovery-pipette-liquid-vial]( "From Sequence To Clinic: Faster Decisions Through In Silico Insights")
In‑silico modeling enables early prediction of molecule stability, formulatability, and risks, reducing lab work, guiding candidate selection, and supporting efficient drug‑product development from sequence to clinic.
-
![GettyImages-1128195910-vial-white-powder-lyophilization]( "Advancing Lyophilization Through Formulation, Process Development")
Lyophilization development and modeling improve stability, streamline freeze‑drying cycles, reduce risks, and support efficient advancement of sensitive formulations.
-
![GettyImages-1409877704-antibody]( "Early Developability Assessment For Smarter Antibody Selection")
Integrated laboratory and in‑silico developability assessments provide early insight into antibody characteristics, reduce risks, streamline decision‑making, and accelerate progress from discovery toward successful drug product development.
-
![GettyImages-1362084368-particles]( "Beyond Detection: Advanced Strategies For Particle Root-Cause Analysis")
Utilize advanced analytical frameworks and machine learning to rapidly identify contaminants, analyze excipient degradation, and perform root cause investigations to ensure stability and compliance.
